Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Vivosim Lab Inc (VIVS)

Vivosim Lab Inc (VIVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
VivoSim Announces Pricing of up to a $4 Million Public Offering GlobeNewswire - Wed Apr 1, 7:05AM CDT

SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS), (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAMs) for preclinical...

VIVS : 1.4800 (+1.35%)
VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs GlobeNewswire - Tue Mar 24, 7:05AM CDT

SAN DIEGO, March 24, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety,...

VIVS : 1.4800 (+1.35%)
VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales GlobeNewswire - Tue Mar 3, 7:05AM CST

SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety,...

VIVS : 1.4800 (+1.35%)
VivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in San Diego GlobeNewswire - Wed Feb 11, 7:05AM CST

SAN DIEGO, Feb. 11, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety,...

VIVS : 1.4800 (+1.35%)
VivoSim Expands Asia-Pacific Access to NAMKind™ Human-Based Toxicology Services Through New Distributor Agreement in Korea and China GlobeNewswire - Thu Jan 29, 3:05PM CST

SAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim Labs”), a provider of next-generation New Approach Methodologies (NAMs) for preclinical...

VIVS : 1.4800 (+1.35%)
VivoSim Labs Appoints Amar Sethi, M.D., Ph.D. as Chief Scientific Officer GlobeNewswire - Tue Jan 6, 7:05AM CST

SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim Labs”), a pharmaceutical and biotechnology services company that is focused on providing...

VIVS : 1.4800 (+1.35%)
VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer GlobeNewswire - Thu Aug 14, 2025

SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim Labs”), a pharmaceutical and biotechnology services company that is focused on providing...

VIVS : 1.4800 (+1.35%)
VivoSim: Fiscal Q1 Earnings Snapshot AP - Tue Aug 12, 2025

VivoSim: Fiscal Q1 Earnings Snapshot

VIVS : 1.4800 (+1.35%)
VivoSim’s NAMKind™ Intestine Wins Blue Ribbon Award at Digestive Disease Week Conference GlobeNewswire - Tue May 13, 2025

VIVS : 1.4800 (+1.35%)
VivoSim Presents Best-in-Class Liver Toxicology Prediction Results at Digestive Disease Week Conference GlobeNewswire - Wed May 7, 2025

VIVS : 1.4800 (+1.35%)

Barchart Exclusives

This Space Stock Just Proved the Bears Wrong Again—Here's What Comes Next Barchart - 57 minutes ago
AST SpaceMobile’s recent dip highlights how short-term setbacks can obscure long-term progress, especially as major regulatory wins reshape its competitive position. The key question now is execution—not viability. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.